A Randomized, Placebo-Controlled Phase 2b Study of Tamibarotene Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin as First Line Treatment for Subjects With Advanced Non-Small Cell Lung Cancer.

Trial Profile

A Randomized, Placebo-Controlled Phase 2b Study of Tamibarotene Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin as First Line Treatment for Subjects With Advanced Non-Small Cell Lung Cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Tamibarotene (Primary) ; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors CytRx Corporation
  • Most Recent Events

    • 07 Jun 2016 Results (n=127) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 02 Jun 2015 Interim results (n=127) presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 16 May 2013 Status changed from active, no longer recruiting to discontinued as reported in a CytRx media release. The independent DSMC found that tamibarotene did result in greater efficacy than approved drugs.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top